Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.

Jan BiegusAdriaan A VoorsSean P CollinsMikhail N KosiborodJohn R Teerlink Christiane E Angermann Jasper TrompJoao Pedro FerreiraMichael E NassifMitchell A Psotka Martina Brueckmann Afshin Salsali Jonathan P Blatchford Piotr Ponikowski

Published in: European heart journal (2022)

Initiation of empagliflozin in patients hospitalized for AHF resulted in an early, effective and sustained decongestion which was associated with clinical benefit at Day 90.

Keyphrases

acute heart failure
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
heart failure
clinical trial
prognostic factors
randomized controlled trial
patient reported outcomes
atrial fibrillation
open label